Since survivin has been suggested to promote tumor-associated angiogenesis and acts as a resistance factor to various anticancer therapies [34], [35], if individuals' drug susceptibility can be predicted by genetic variation such as the survivin −31G>C polymorphism, the efficacy of these drugs may be further enhanced. Here, BIRC5 is linked to neoplasm.